Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eli Lilly
(NY:
LLY
)
877.79
-31.53 (-3.47%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
99
100
Next >
Markets Up On Tesla, Q1 Earnings; Q1 Beats After The Bell
April 30, 2024
Market indices finished in the green across the board this Monday. It’s now the third straight day higher going back to Thursday of last week, and recovered from a quick drop into the red (mostly)...
Via
Talk Markets
Here's How Much Stock Eli Lilly Repurchased in 2023
April 29, 2024
Hint: It probably wasn't as much as you might imagine given the company's immensity.
Via
The Motley Fool
How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q1 Earnings Report
April 29, 2024
Eli Lilly investors may be eyeing potential gains from dividends. The company is currently offering an annual dividend yield of 0.71%.
Via
Benzinga
Nasdaq Bull Market: Here's the Best Investing Move You Can Make Right Now
April 29, 2024
Many technology stocks are soaring, and you may be wondering if they've gotten too expensive.
Via
The Motley Fool
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
April 29, 2024
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Eli Lilly Just Announced More Good News: Time to Buy?
April 28, 2024
There's no stopping this high-flying biotech.
Via
The Motley Fool
Market Whales and Their Recent Bets on LLY Options
April 23, 2024
Via
Benzinga
Is Viking Therapeutics Incredibly Undervalued?
April 28, 2024
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.
Via
The Motley Fool
Forget Nvidia, These Unstoppable Stocks Are Better Buys
April 27, 2024
These stocks have tremendous potential, and it doesn't depend on the growth prospects for artificial intelligence.
Via
The Motley Fool
1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On
April 27, 2024
Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.
Via
The Motley Fool
3 Dividend Stocks to Buy and Hold for the Next Decade
April 27, 2024
You'll get dividends and more with these great stocks.
Via
The Motley Fool
MarketBeat Week in Review – 4/22 - 4/26
April 27, 2024
Investors continue to look for clarity as tech earnings sent stocks higher to end the week, even as investors hope for rate cuts fade as inflation rises
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
SPDR ETF Report For Friday, April 26
April 27, 2024
Via
Talk Markets
Topics
ETFs
Jim Cramer Weighs In Ahead Of Apple, Amazon, Eli Lilly Earnings: 'We Have To Run Such A Ridiculous Gauntlet Next Week'
April 26, 2024
Jim Cramer has highlighted upcoming significant events for investors, including earnings from major companies like Apple and Amazon, and key economic indicators such as the Federal Reserve meeting and...
Via
Benzinga
Topics
Economy
Exposures
Economy
Interest Rates
ResMed Soars To Eight-Month High As Quarterly Report Wipes Out Weight-Loss Woes
April 26, 2024
ResMed is the biggest maker of CPAPs in the U.S., and says the growing popularity of weight-loss drugs could help diagnosis rates.
Via
Investor's Business Daily
Dividend Legends: 3 Stocks With Over 100 Years of Payouts
April 25, 2024
Dividend payers are companies that have stood the test of time and these dividend stocks with 100+ years of payouts lead them all.
Via
InvestorPlace
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
April 25, 2024
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.
Via
Investor's Business Daily
Don’t Miss Out! 3 Top-Tier Blue-Chip Growth Stocks for Your Must-Buy List
April 25, 2024
These three large-cap blue-chip growth stocks are certainly worth considering as core portfolio holdings in this current environment.
Via
InvestorPlace
Which Companies Will Join the Trillion-Dollar Team in 2024? Our 3 Best Guesses
April 24, 2024
Explore the dynamics of money-maker stocks in 2024, which are fueled by AI advancements and robust economic growth.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
April 24, 2024
Senate Committee probes Novo Nordisk's pricing tactics for diabetes and obesity meds. Sanders demands transparency on pricing, signaling broader industry scrutiny. Medicare coverage expansion could...
Via
Benzinga
Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market
April 24, 2024
Lilly recently announced news that could solve a big problem.
Via
The Motley Fool
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
April 24, 2024
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly.
Via
InvestorPlace
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
April 24, 2024
Good news could be just around the corner for two drugmakers not named Novo Nordisk.
Via
The Motley Fool
REITs Q1 Earnings Begin On Solid Note
April 23, 2024
Via
Benzinga
Better Buy: Pfizer vs. Viking Therapeutics
April 23, 2024
These two pharma stocks have followed distinct paths of late. Which is the better investment?
Via
The Motley Fool
3 Stocks With the Potential to Surpass Analyst Expectations for 2024
April 23, 2024
These stocks to buy are set to surpass analyst expectations, with exciting product and service developments sparking unforeseen growth.
Via
InvestorPlace
Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires Manufacturing Facility From Nexus Pharma
April 22, 2024
Eli Lilly expands its global manufacturing network with FDA-approved facility acquisition in Pleasant Prairie, Wisconsin. Boosting production to meet growing demand for medicines, including GLP-1...
Via
Benzinga
7 High-Flying Stocks That Are Majorly Overdue for a Pullback
April 22, 2024
After performing strongly since the start of the year, it's time to sell these stocks due for a pullback before they reverse course.
Via
InvestorPlace
Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending
April 22, 2024
Discover how GLP-1 drugs reshape consumer spending in food industries. Novo Nordisk's Wegvoy and Eli Lilly's Zepbound gain traction, altering dining habits.
Via
Benzinga
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
April 22, 2024
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio
Via
MarketBeat
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.